Pfizer's top products based on revenue 2023
The graph depicts Pfizer's top 10 products based on revenue in 2023. Pfizer Inc. is a multinational pharmaceutical corporation. The company is headquartered in Midtown Manhattan, New York City. In 2023, Pfizer's top product was again COVID-19 vaccine Comirnaty, although with a dramatic drop in sales from 37.8 billion U.S. dollars in 2022 to 11.2 billion dollars.
Pfizer's top products
Pfizer is a pharmaceutical corporation headquartered in New York City, United States. It was founded in 1849 by Charles Pfizer and Charles Erhart in Brooklyn, New York, where they produced an antiparasitic called santonin. Today, Pfizer produces pharmaceutical products for a wide range of medical sectors that include but are not limited to immunology, cardiology, and neurology. In 2023, Pfizer generated total revenue of 58.5 billion U.S. dollars worldwide with oncology products accumulating some 11.6 billion U.S. dollars. In the same year, Pfizer generated 46 percent of its revenues in the United States.
Some of Pfizer’s well-known products - although with expired patent protection - include Lyrica and Lipitor, which generated around 3.3 and five billion U.S. dollars in revenue, respectively, in 2019. Pregabalin, marketed as Lyrica, is an anticonvulsant drug used to treat disorders such as epilepsy, diabetic peripheral neuropathy, and fibromyalgia. Lipitor, one of Pfizer’s more well-known products, generated revenues of 12.9 billion U.S. dollars in 2006, however, after Pfizer’s patent on Lipitor expired in 2011, revenue has fallen to under two billion U.S. dollars. Currently, generic forms of atorvastatin (Lipitor) are available. Lipitor is a statin that is used to lower blood cholesterol and to prevent cardiovascular diseases.
Pfizer's top products
Pfizer is a pharmaceutical corporation headquartered in New York City, United States. It was founded in 1849 by Charles Pfizer and Charles Erhart in Brooklyn, New York, where they produced an antiparasitic called santonin. Today, Pfizer produces pharmaceutical products for a wide range of medical sectors that include but are not limited to immunology, cardiology, and neurology. In 2023, Pfizer generated total revenue of 58.5 billion U.S. dollars worldwide with oncology products accumulating some 11.6 billion U.S. dollars. In the same year, Pfizer generated 46 percent of its revenues in the United States.
Some of Pfizer’s well-known products - although with expired patent protection - include Lyrica and Lipitor, which generated around 3.3 and five billion U.S. dollars in revenue, respectively, in 2019. Pregabalin, marketed as Lyrica, is an anticonvulsant drug used to treat disorders such as epilepsy, diabetic peripheral neuropathy, and fibromyalgia. Lipitor, one of Pfizer’s more well-known products, generated revenues of 12.9 billion U.S. dollars in 2006, however, after Pfizer’s patent on Lipitor expired in 2011, revenue has fallen to under two billion U.S. dollars. Currently, generic forms of atorvastatin (Lipitor) are available. Lipitor is a statin that is used to lower blood cholesterol and to prevent cardiovascular diseases.
